Skip to main content

venBio Global Strategic Fund IV, L.P.'s Form 4 filing

Attovia Therapeutics, Inc.ATTO · filed Aug 10, 2026

Accession no.
0000905148-26-003548
Filed
Aug 10, 2026, 4:12 PM ET
Trade date
Aug 6, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $6.50M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
venBio Global Strategic Fund IV, L.P.CIK 000186210910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 6, 2026Common StockCConversionAcquired+2,311,870–F1–2,311,870Direct
Aug 6, 2026Common StockCConversionAcquired+821,998–F1–3,133,868Direct
Aug 6, 2026Common StockCConversionAcquired+665,147–F1–3,799,015Direct
Aug 6, 2026Common StockPPurchaseAcquired+382,352$17.00+$6,499,9844,181,367Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 6, 2026Common StockCConversionDisposed−2,311,870$0.00$00Direct
Aug 6, 2026Common StockCConversionDisposed−821,998$0.00$00Direct
Aug 6, 2026Common StockCConversionDisposed−665,147$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)